Research Analysts Issue Forecasts for CRBP Q1 Earnings

Key Points

• Analysts at Wedbush have forecasted that Corbus Pharmaceuticals will report a Q1 2026 earnings per share of ($1.15), maintaining an "Outperform" rating with a price target of $38.00.
• Corbus Pharmaceuticals has experienced significant interest from hedge funds, with 64.64% of its stocks held by institutional investors after recent buy-ins from firms like Comerica Bank and Aberdeen Group.
• The company has seen a remarkable 342% YTD surge in its stock price, with shares opening at $19.36 and a market cap of approximately $237.26 million.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Analysts at Wedbush issued their Q1 2026 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Monday, October 20th. Wedbush analyst R. Driscoll forecasts that the biopharmaceutical company will post earnings per share of ($1.15) for the quarter. Wedbush has a "Outperform" rating and a $38.00 price objective on the stock. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share. Wedbush also issued estimates for Corbus Pharmaceuticals' Q2 2026 earnings at ($1.32) EPS, Q3 2026 earnings at ($1.09) EPS, Q4 2026 earnings at ($1.15) EPS and FY2026 earnings at ($4.68) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.44) EPS for the quarter, beating the consensus estimate of ($1.55) by $0.11.

Other analysts have also issued reports about the company. Lifesci Capital raised Corbus Pharmaceuticals to a "strong-buy" rating in a research report on Saturday, July 12th. B. Riley raised Corbus Pharmaceuticals to a "strong-buy" rating and set a $28.00 target price on the stock in a research report on Wednesday, July 30th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, October 8th. Benchmark reaffirmed a "reduce" rating on shares of Corbus Pharmaceuticals in a research report on Monday. Finally, Oppenheimer dropped their target price on Corbus Pharmaceuticals from $56.00 to $53.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, Corbus Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $45.86.

Corbus Pharmaceuticals Stock Performance

Shares of NASDAQ CRBP opened at $19.36 on Wednesday. Corbus Pharmaceuticals has a 1 year low of $4.64 and a 1 year high of $20.77. The firm has a market cap of $237.26 million, a price-to-earnings ratio of -4.07 and a beta of 2.84. The stock's 50-day simple moving average is $12.02 and its 200-day simple moving average is $9.23.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Comerica Bank grew its stake in Corbus Pharmaceuticals by 20,000,000.0% in the first quarter. Comerica Bank now owns 200,001 shares of the biopharmaceutical company's stock worth $1,062,000 after purchasing an additional 200,000 shares in the last quarter. Exome Asset Management LLC acquired a new position in Corbus Pharmaceuticals in the first quarter worth about $1,538,000. Aberdeen Group plc boosted its stake in Corbus Pharmaceuticals by 168.6% in the second quarter. Aberdeen Group plc now owns 72,226 shares of the biopharmaceutical company's stock valued at $498,000 after acquiring an additional 45,332 shares during the period. Acadian Asset Management LLC acquired a new position in Corbus Pharmaceuticals in the first quarter valued at approximately $1,007,000. Finally, Atle Fund Management AB boosted its stake in Corbus Pharmaceuticals by 78.6% in the second quarter. Atle Fund Management AB now owns 175,582 shares of the biopharmaceutical company's stock valued at $1,212,000 after acquiring an additional 77,278 shares during the period. 64.64% of the stock is currently owned by institutional investors and hedge funds.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.